上海地区α-干扰素治疗慢性乙型肝炎的药物经济学分析

通过比较α-干扰素治疗慢性乙型肝炎的费用和收益,从经济方面分析在我国这种治疗的意义.结果表明这种治疗不仅可拯救生命、延长病人的存活时间,而且可大大改善病人的生活质量.在经济方面,用α-干扰素治疗慢性乙型肝炎的成本效益比值(干扰素的治疗费用/因治疗而节省的费用)为1.22,即每投入1元可节省医疗费用1.22元;若同时计算因病休损失的社会费用,成本效益比值为3.02,平均每年为社会减少大量的由肝病导致的经济损失.提示在上海地区用α-干扰素治疗慢性乙型肝炎病人具有重要的医学和经济意义.

PHARMACO-ECONOMIC STUDY:INTERFERON ALFA TREATMENT OF CHRONIC HEPATITIS B IN SHANGHAI

In this article the costs and benefits of interferon alfa treatment of chronic hepatitis B in Shanghai were evaluated to assess the long -term economic impact. This treatment will not only save lives and prolong the average life year by more than 1 year,but also improve the life quality. When economic is concerned, the ratio of costs to benefits (in RMB) is 1.22 and up to 3.02 when social cost (value of work absence result from hepatic disease)is included. This study indicates that in Shanghai both the medical care payer (ie,the insurance plan)and the society will economically benefit from the treatment of chronic hepatitis B with interferon alfa.